Purple Biotech Enters Research Collaboration for Breakthrough Cancer Treatments
Purple Biotech is proud to announce a promising research collaboration with the prestigious Icahn School of Medicine at Mount Sinai. This partnership will focus on innovative strategies to enhance tumor immunity against various cancers through the company’s CAPTN-3 tri-specific antibody platform.
Understanding the Tumor Microenvironment
The primary goal of this collaborative effort is to investigate the immunoregulation of natural killer (NK) and T cells within the tumor microenvironment (TME) using CAPTN-3. By fostering a stronger, more targeted immune response, Purple Biotech aims to improve therapeutic outcomes for patients battling resistant tumors.
Advancing NK and T Cell Functionality
CAPTN-3 antibodies have been specially crafted to enhance the antitumor activities of innate-like immune cells, particularly NK and CD8 T cells. This is achieved through a refined approach that encourages conditional activation of the anti-CD3 arm within the TME, blocks inhibitory signals like NKG2A, and selectively targets tumor-specific antigens. Consequently, these mechanisms could lead to remarkable efficacy for patients who do not respond to current cancer treatments.
Insights from Leading Immunologists
Gil Efron, CEO of Purple Biotech, expressed optimism regarding this collaboration. “We are excited to work with the team at the Marc and Jennifer Lipschultz Precision Immunology Institute and The Tisch Cancer Institute. This research is crucial as we push toward human clinical trials for CAPTN-3,” he stated.
The Role of Dr. Amir Horowitz
The study will be led by Dr. Amir Horowitz, an Associate Professor specializing in immunology and oncological sciences. Dr. Horowitz has pioneered research on the HLA-E and NKG2A signal pathway, which plays a central role in immune suppression observed in cancer patients. His efforts to unravel these mechanisms will be vital in testing how CAPTN-3 alters the activation of both NK and T cells.
What This Means for Future Therapies
This collaboration symbolizes a significant advancement in understanding and addressing tumor immune evasion. Purple Biotech's VP of Research and Development, Dr. Hadas Reuveni, revealed the exciting potential of CAPTN-3, stating, “This partnership brings us one step closer to unveiling the distinctive aspects of CAPTN-3's design in various patient-derived tumors, ultimately offering new avenues to overcome the resistance encountered with standard frontline therapeutics.”
Company Commitments and Future Directions
Purple Biotech is steadfast in its commitment to developing leading-edge therapies that confront the challenges of immune evasion and drug resistance in cancer treatment. The oncology pipeline, which includes flagship candidates such as CM24, NT219, and CAPTN-3, illustrates their extensive research efforts aimed at dissecting complex cancer biology.
About Purple Biotech and Its Innovations
Purple Biotech Ltd. (NASDAQ: PPBT) is a clinical-stage entity heralding innovative therapies targeting tumor immune evasion and drug resistance. Its versatile oncology pipeline integrates CM24, NT219, and CAPTN-3, each targeting robust biological pathways to enhance patient outcomes. CM24, for instance, is a humanized monoclonal antibody aiming to inhibit CEACAM1, a vital player in tumor survival across various cancer types.
Partnerships and Clinical Studies
Purple Biotech continues to expand its collaborative framework and is engaged in active clinical studies assessing the efficacy and safety of its therapeutics. The completion of a Phase 2 study to explore CM24 in conjunction with PD-1 inhibitors demonstrates their capability to yield effective therapeutic combinations that stand to benefit cancer patients.
Frequently Asked Questions
What is the focus of the research collaboration between Purple Biotech and Icahn School of Medicine?
The collaboration aims to explore the immunoregulation of NK and T cells in the tumor microenvironment using Purple Biotech's CAPTN-3 antibody platform to enhance tumor-specific immunity.
Who is leading the study on CAPTN-3?
Dr. Amir Horowitz, an expert in immunology and cancer, is leading the research, focusing on how CAPTN-3 can improve T and NK cell activation.
Why is CAPTN-3 significant for cancer therapies?
CAPTN-3 has the potential to offer new treatment avenues for patients with resistant cancers by enhancing innate immune responses and overcoming current therapeutic limitations.
What are the potential benefits of the CAPTN-3 antibodies?
These antibodies can conditionally activate T cells and NK cells, block inhibitory pathways, and directly engage tumor-specific antigens to facilitate a stronger immune attack on tumors.
How is Purple Biotech advancing its research efforts?
Purple Biotech is actively conducting clinical studies and collaborations to deepen its understanding of immunotherapy, with the ultimate goal of bringing innovative therapies to market for challenging cancer types.
